Advances in Novel Biomarkers and Emerging Immune/Targeted Therapies in Solid Tumors
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: 31 May 2025 | Viewed by 102
Special Issue Editors
Interests: biomarker; onco-immunology; lung cancer; precision oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent years, cancer research has experienced transformative advancements, particularly in our molecular understanding of solid tumors. Cutting-edge techniques such as genomic profiling, liquid biopsies, and onco-immunotherapy are revolutionizing how we approach cancer treatment, moving from a one-size-fits-all paradigm to a more precise, patient-centered model.
Immunotherapy and targeted therapies now represent key pillars in cancer treatment. Initially, immune checkpoint inhibitors (ICIs) and targeted therapies were limited to advanced or metastatic settings, often as salvage treatments in conjunction with chemotherapy. However, over the past decade, breakthroughs in these therapies have expanded their use to earlier stages, including neoadjuvant and adjuvant settings for resectable solid tumors. Clinical trials demonstrating their promise have led to the FDA approving several novel therapies for early-stage non-small-cell lung, breast, and bladder cancer and melanoma, among others. This paradigm shift offers the possibility of curing many early-stage cancer patients through the integration of immunotherapy and targeted treatments.
Our Special Issue, “Advances in Novel Biomarkers and Emerging Immune/Targeted Therapies in Solid Tumors”, guest-edited by Dr. Weijie Ma and Dr. Liang Lu, aims to gather groundbreaking research and reviews that enhance our understanding of the molecular mechanisms driving solid tumors and explore the clinical applications of targeted and immunotherapies. We encourage submissions covering a broad spectrum—from well-established molecular targets and emerging biomarkers to innovative treatment strategies. Topics of particular interest include overcoming acquired resistance to therapies, managing the side effects of these new treatments, integrating molecular therapies into existing treatment regimens, the role of pathological evaluation in optimizing therapies, and using tissue- and blood-based biomarkers for therapy selection and response monitoring.
We invite submissions from various disciplines, including molecular biology, pathology, pharmacology, and clinical oncology, to comprehensively collect the latest insights, aiming to enhance patient outcomes and guide future research in this rapidly evolving field.
Dr. Weijie Ma
Dr. Liang Lu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- solid tumor
- biomarker
- molecular targets
- tyrosine kinase inhibitors (TKIs)
- immune checkpoint inhibitors (ICIs)
- oncogenic driver mutation
- acquired resistance
- precision oncology
- cancer
- next-generation sequence
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
